Profit of 111In-Pentetreotide scintigraphy (OCTREOSCAN) in the broncho-pulmonary cancers

The aim of this study was to determine the sensitivity of the scintigraphy of somatostatin receptors in detecting the primary and metastatic sites. A prospective multi-center study including 54 patients (49 M, 5 F, average age 60 ± 9 years) carrying a broncho-pulmonary cancer was carried out as follows: 17 small cell carcinomas (SCC), 15 adenocarcinomas (ADC), 14 epidermoid carcinomas (EC), 7 un-differentiated carcinomas (UDC) and a mixed carcinoma. The planar images of skull, thorax, abdomen and pelvis were done 4 h and 24 h after injecting about 110 MBq of 111In-Pentetreotide. The T/B ratio was determined at 4 h and at 24 h. The results of scintigraphy were compared with the usual extension account. A table is given showing the T/B ratio at 0D and 1D for SCC, ADC, EC and UDC, respectively. The primary tumors were detected with a 100% sensitivity, independently of the histologic type. The UDC were in average more fixating than the other types of tumors. The gap is significant (p = 0.05) relative to the ADC, at 24 h. Visually, the fixation of the primary site seems to pass beyond the anatomic limits of the tumor. The metastatic stretches (all the sites merged) were visualized in 37% of cases. In exchange, the scintigraphy is clear more performing in detecting the cerebral metastases (sensitivity: 70%) particularly, in the SCC (sensitivity: 100%). In conclusion, the Octreoscan scintigraphy is highly sensible in the detection of the primary broncho-pulmonary cancers of any types and seems to be of interest in detecting the cerebral metastases